InvestorsHub Logo
Followers 0
Posts 1
Boards Moderated 0
Alias Born 04/28/2014

Re: None

Thursday, 05/21/2015 9:27:36 AM

Thursday, May 21, 2015 9:27:36 AM

Post# of 161
I think ERBA is on the cusp of growth . They are just 3 year old compny with big plans on acquisition and merger. Strong back up by Suresh an entrepreneur the 82% owner of this company. Lots of global spread and incresing account receivables. They need to work on account receivables. Mohan the CEO said in the OneMed their focus will be more on US growth in 2015. Time horizon for merger and folding of all global ERBA units(currently $200M rev) in the next 3 to 5 years. US sales target of $100 to 150 M in the next 3 to 5 years. Consistent profitability is their motto. Immunology and molecular technology appears to be their next target segment. Good source for consistent revenue. Acquisitions in Latin America (Brazil). The best part is the exponential growth on the reagents sales Y over Y. They are planning to grow by selling their instruments cheaply.The new marketing guy seems to have lots of experience. They can become a $500M(Mohan says 1Billion) rev company in 5 years with the added dilution and a total of say 100 million shares .I based it on purchase of all private ERBAs 20% of the $200 revenue+ inventories at a $5 value). If the profits keep growing with increasing margins and consolidation I would guess the stock price will be $15 or more easily in 5 years (based on 3x 500M revenue market cap). Any other meaningful thoughts ?

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.